CN100548384C - A kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application - Google Patents
A kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application Download PDFInfo
- Publication number
- CN100548384C CN100548384C CNB2006101476646A CN200610147664A CN100548384C CN 100548384 C CN100548384 C CN 100548384C CN B2006101476646 A CNB2006101476646 A CN B2006101476646A CN 200610147664 A CN200610147664 A CN 200610147664A CN 100548384 C CN100548384 C CN 100548384C
- Authority
- CN
- China
- Prior art keywords
- gene
- adjuvant
- plasmid
- expression
- pig
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the gene engineering field, be specially a kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application.The adjuvant that the present invention relates to is to utilize Protocols in Molecular Biology to be cloned into the recombiant plasmid that carrier for expression of eukaryon obtains man pig interferon-α gene.Wherein tame pig interferon-α gene is meant the gene of the arbitrary hypotype in tame pig interferon-α multigene family; Carrier for expression of eukaryon can be to have any DNA expression vector that eukaryotic promoter, protokaryon replicon and protokaryon resistant gene are feature.This recombiant plasmid changes the escherichia coli amplification over to and obtains a large amount of plasmids by alkaline lysis, and dilutes plasmid to finite concentration with the PBS buffer, is mixed with polypeptide vaccine adjuvant of the present invention.Animal experiment proves that this adjuvant safety is good, and effect is remarkable, with the coupling of O type foot-and-mouth disease gene engineering vaccine, can have ideal preventive effect to foot and mouth disease virus behind the inoculation man pig, and the protected rate of domestic animal reaches 100%.
Description
Technical field
The invention belongs to the gene engineering field, be specially a kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application.
Background technology
Foot and mouth disease (foot-and-mouth disease, FMD) be one of livestock contagious disease the most serious in the world today, cloven-hoofed animals such as main harm pig, cattle, sheep, and the outburst scope is wide, propagate rapidly, the mortality rate height causes enormous economic loss to animal husbandry behind the zoogenetic infection, thereby is classified as first of the category-A infectious disease by World Organization for Animal Health.
Advantages such as gene engineering polypeptide vaccine is easy to preserve because safety is good, and is satisfactory for result have broad application prospects.Yet the recombinant vaccine immunogenicity relatively a little less than, for the immune system of excitating organism better, make it have enough resistances, be necessary to seek the immunocompetence that more simple and effective method improves gene engineering polypeptide vaccine foot and mouth disease virus (FMDV).
Strengthen the active method of vaccine immunity and not only depend on the formation of improving related antigen component in the vaccine, depend on that also adding suitable adjuvant comes stimulating immune system, improves the immunne response to antigenic substance.Ideal adjuvant should specific auxiliary boosting vaccine immune system, can not have side effects to animal simultaneously.Interferon-' alpha ' (Interferon, IFN-α) is the cytokine family that a class has antivirus action, and under normal physiological conditions, it only has a small amount of constitutive expression in animal body; But when virus or bacterial infection animal body, this cytokine is used for body cell by a large amount of abduction deliverings and resists the cause of disease invasion.In recent years, the good immunoloregulation function of IFN-α is found and becomes immunologic research focus.This comprises that activating the B cell also assists the quick polyclonal antibody that produces at cause of disease of B cell; Induce the increment of NK cell and T cell and increase its cytotoxic activity; The growth of auxiliary CD8+ memory T cell, the life span that prolongs memory T cell; And the immunostimulatory cell factors such as IFN-γ, IL-1 β, IL-2, IL-6 had the up-regulated effect.Above achievement in research shows to have feasibility with IFN-α in theory as the immunocompetence that adjuvant improves gene engineering polypeptide vaccine.There is document to show and carried out the related work of tame pig IFN-α abroad as adjuvant and vaccine coupling prevention foot and mouth disease.Its content is for to be cloned into tame pig IFN-α in people's recombinant adenovirus 5 (h-Ad5) carrier for expression of eukaryon; with the A type foot and mouth disease recombinant DNA vaccine coupling that with h-Ad5 is carrier; have pair foot and mouth disease virus that desirable preventive effect is arranged behind the inoculation man pig, the protected rate of domestic animal is 80%.
Summary of the invention
The objective of the invention is to propose a kind of genetic engineering polypeptide vaccine adjuvant for aftosa based on the DNA carrier for expression of eukaryon and preparation method thereof, and this adjuvant is applied to animal body assesses its effect.
The genetic engineering polypeptide vaccine adjuvant that the present invention proposes is to be cloned into the recombiant plasmid that carrier for expression of eukaryon obtains by tame pig interferon-α gene by Protocols in Molecular Biology.Wherein, tame pig interferon-α functional gene is meant the arbitrary subtype gene in the tame porcine alpha-interferon gene family, and carrier for expression of eukaryon can be to have arbitrary DNA expression vector that eukaryotic promoter, prokaryotic promoter and protokaryon resistant gene are feature.
Family's pig interferon-α gene family one has 14 interferon-' alpha ' functional genes, and the nucleotide homology of this each subtype gene of gene family reaches 96%-100%.It is to comprise that 23 amino acid whose signal peptides and total length are 189 amino acid whose complete genomes that 8 functional genes are wherein arranged, and it is to comprise that 23 amino acid whose signal peptides and total length are 181 amino acid whose complete genomes that 6 functional genes are arranged.Each functional gene in the family all has similar immune stimulatory, is used as the function of adjuvant.The interferon-' alpha ' gene that the present invention relates to can be the gene of arbitrary hypotype in tame pig interferon-α multigene family.In application example, the aminoacid sequence of tame pig interferon-α gene code is SEQ ID NO.1, and its nucleotides sequence is classified SEQID NO.2 as.
This foot-and-mouth disease gene engineering polypeptide vaccine novel adjuvant is to make up to form on the basis of carrier for expression of eukaryon.The DNA carrier for expression of eukaryon can be any eukaryon expression plasmid with following feature:
(1) makes up the used carrier for expression of eukaryon of this eukaryon expression plasmid and have the protokaryon replicon simultaneously;
(2) this plasmid has eukaryotic promoter;
(3) this plasmid has protokaryon selection resistant gene and suitable multiple clone site, is convenient to gene and inserts and screen.
The applied carrier for expression of eukaryon of the present invention specifically is to have arbitrary dna vector that eukaryotic promoter, protokaryon replicon and protokaryon resistant gene are feature.The pcDNA eukaryon expression plasmid that uses among the embodiment (Invitrogen company product) has pUC ori replicon and amp resistant gene when having SV40 replicon and CMV promoter.Except that pcDNA, the carrier for expression of eukaryon that other series have this feature all can be as the structure of adjuvant.
We obtain from the total RNA of tame pig liver to comprise that by the method for RT-PCR 23 amino acid whose signal peptides and total length are 189 the amino acid whose pig IFN-α of family genes among the embodiment, with EcoR I and Xho I is that restriction enzyme site inserts expression vector pcDNA3, and is transformed in the escherichia coli.
The preparation method of adjuvant of the present invention comprises steps such as gene preparation, reorganization, protein active mensuration, the extensive extracting of plasmid, and is specific as follows:
(1) method by RT-PCR obtains IFN-α complete genome from the total RNA of tame pig liver, and in force, its nucleotides sequence is classified SEQ ID NO.2 as;
(2) said gene is inserted procaryotic clone carrier, and transformed into escherichia coli, order-checking also compares with tame pig IFN-α sequence that GenBank provides, has determined to obtain correct gene;
(3) said gene is inserted the construction of eukaryotic expression vector recombiant plasmid, and transformed into escherichia coli, extracting plasmid transfection BHK-21 cell, continued cultured cell 40-50 hour, collect the supernatant culture medium and utilize WISH cell/vesicular stomatitis virus (Vesicular Stomatitis Virus) activity determining system and PK15 cell/Pseudorabies virus (Pseudorabies Virus) activity determining system to measure tame pig IFN-alpha active respectively, determine the tame pig IFN-α albumen that the recombiant plasmid that makes up can expression activity.
(4) positive strain was collected thalline at 35-40 ℃ of fermentation culture 10-15 hour; Broken thalline is also used alkaline lysis mass preparation expression vector plasmid; Utilize PBS buffer dilution plasmid to suitable concentration, be mixed with polypeptide vaccine adjuvant of the present invention.
The present invention also proposes the application of described adjuvant, specifically is with itself and foot-and-mouth disease gene engineering polypeptide vaccine joint injection animal.Prove that this adjuvant can effectively assist boosting vaccine animal body immunne response.This adjuvant and the coupling of O type foot-and-mouth disease gene engineering polypeptide vaccine in an embodiment can have ideal preventive effect to foot and mouth disease virus behind the inoculation man pig.
The O type foot-and-mouth disease gene engineering polypeptide vaccine (patent No.: 02137011.7) that the present invention relates to, be to be carrier protein from body IgG with tame pig, the foot-and-mouth disease virus antigen polypeptide chain is connected on the C-terminal of carrier protein, constitute a fusion rotein, wherein antigen polypeptide adopts in the foot and mouth disease virus VP1 albumen and has antigenic amino acid peptide section, and it is formed the cascaded structure of multicopy, add amino acid polypeptide in peptide section junction as joint.
Among the embodiment foot-and-mouth disease virus antigen polypeptide chain is connected on the C end of carrier protein, constitutes fusion rotein.After making antigen polypeptide be expressed as fusion rotein, can embody antigenicity better, we have suitably chosen the IgG CH as carrier protein, adopt among the embodiment as described later the 30th to 328 of pig IgG CH totally 299 amino acid peptide sections as carrier protein; The FMDV antigen polypeptide then adopts 3 major antigen epi-positions in the O type foot and mouth disease virus VP1 albumen, i.e. 21 へ 40,141 へ 160,213 3 amino acid peptide sections of 200 へ, and it is formed the cascaded structure of 141 へ 160AA-21 へ 40AA (or 200 へ 213AA)-141 へ 160AA, add suitable amino acid polypeptide as joint in peptide section junction, adopt the antigen polypeptide structure of 141 へ 160AA (" Y ")-Pro-Gly (" M ")-21 へ 40AA (" X ")-Gln-Phe-Glu-Leu-Glu-Phe-Met-Val-Pro-Ser-Arg (" N ")-141 へ 160AA (" Y ") as described later among the embodiment, former and later two joints are respectively 2 and 11 aminoacid.
Its architectural feature is as follows:
Respectively there is the DNA sequence of coding 141 へ 160 amino acids of a copy at the two ends of antigen gene, and the centre is the DNA sequence of coding 21 へ 40 amino acids of a copy; Two joints that connect these sequences are respectively 2 and 11 aminoacid.
On gene level, this cascaded structure is connected the C-terminal of IgG CH, forms fusion gene, express obtaining fusion rotein.This fusion rotein has following characteristics:
(1) on gene level, carrier protein gene size is about 900bp, and antigenic peptides gene size is about 240bp, and whole fusion gene size is about 1.2kb.
(2) on protein level, carrier protein only comprises the 30th of pig IgG CH to the 328th amino acids peptide section, i.e. 299 aminoacid; Antigen polypeptide is above-mentioned tandem polypeptide section, and wherein 21 へ, 40 amino acids peptide sections are t cell epitopes, and 141 へ, 160 amino acids peptide sections are B cell epitopes.Whole fusion protein molecule amount is about 50kDa.
The invention still further relates to the application process of this adjuvant.Its advantage of the adjuvant that the present invention relates to can reduce the consumption of recombinant vaccine when being with the recombinant vaccine coupling, and need only carry out combined immunization with polypeptide vaccine and can make animal body produce enough immunity, and lasting medicine makes the animal of immunity have ideal preventive effect to foot and mouth disease virus.
The tame pig IFN-α that the present invention relates to is as the immunostimulation factor, not only can directly utilize recombiant plasmid, recombiant plasmid can also be changed over to the pig attenuation salmonella or tame pig interferon-α gene is linked to each other as vaccine adjuvant with recombinant adenoviral vector as vaccine adjuvant.Because IFN-α stimulating immune system has the characteristics of broad spectrum activity, therefore the novel adjuvant of the present invention's proposition not only can be united use with O type foot-and-mouth disease gene engineering polypeptide vaccine, can also with the foot-and-mouth disease virus gene engineered polypeptide vaccine coupling of other hypotypes, the prevention different subtype foot and mouth disease virus.Simultaneously, we also propose: this adjuvant is widely used in the different strains that susceptible animal prevents the homotype foot and mouth disease virus with the FMDV gene order of a certain strain of a certain type for the vaccine according to structure, reason is that variation is less between the different strains of homotype foot and mouth disease virus, with the animal of this adjuvant and vaccine combined immunization these strains is had cross immunity power.
Novel adjuvant and O type foot-and-mouth disease gene engineering polypeptide vaccine that the present invention is proposed carry out the immune efficacy check.Attack with O type foot and mouth disease virus behind the certain hour not by the pig of natural infection so that a certain amount of this combined vaccine is once immune, the result shows that this adjuvant and vaccine coupling have very good protection effect (seeing Table 1) to laboratory animal.Utilize solid phase blocking-up ELISA to detect after the virus attack that the result of viral non-structural protein antibody shows in the animal serum, the animal of adjuvant and vaccine combined immunization is virus-free duplicating (seeing Table 2) in virus attack 7 days and 14 days later bodies.
The immune protective effect of table 1 adjuvant and vaccine combined immunization animal
Annotate: adjuvant: interferon dna 2mg; Polypeptide vaccine: IgG-FMDV recombiant protein 6mg
Viral non-structural protein antibody test in the serum behind the table 2 virus attack vaccine immunity animal
Annotate 1: adjuvant: interferon dna 2mg; Polypeptide vaccine: IgG-FMDV recombiant protein 6mg
Annotate 2: utilize solid phase blocking-up ELISA to measure non-structural protein antibody in the animal serum, data are the meansigma methods of three animal blocking-up percentage rate rates.
When non-structural protein blocking-up rate 〉=20%, can judge zoogenetic infection virus, illustrate that virus duplicates in animal body.
The specific embodiment
Be that example further specifically describes the present invention with Schweineseuche O-shaped gene engineering polypeptide vaccine with the novel adjuvant that the present invention relates to below.
The building process of adjuvant.Obtain tame pig liver sample and utilize total RNA extraction agent (Trizol, Invitrogen company product) extracting liver total RNA, method by RT-PCR obtains from the total RNA of tame pig liver to comprise that 23 signal peptides and total length are 189 the amino acid whose pig IFN-α of family genes, its nucleotides sequence is classified SEQ.ID.NO.2 as, its amino acid sequence coded is SEQ.ID.NO.1, said gene is inserted procaryotic clone carrier pMD18-T (TaKaRa company product), and transformed into escherichia coli TG1, picking positive colony order-checking also compares with tame pig IFN-α sequence that GenBank provides, has determined to obtain correct gene; Is that restriction enzyme site inserts carrier for expression of eukaryon pcDNA3.1 (Invitrogen company product) with said gene with EcoRI and XhoI, and transformed into escherichia coli, the positive colony called after pcDNA-IFN of acquisition.Extracting pcDNA-IFN plasmid transfection BHK-21 cell, continued cultured cell 40-50 hour, collect the supernatant culture medium and utilize WISH cell/vesicular stomatitis virus (Vesicular Stomatitis Virus) activity determining system and PK15 cell/Pseudorabies virus (Pseudorabies Virus) activity determining system to measure tame pig interferon-alpha active respectively, determine the tame pig IFN-α albumen that the recombiant plasmid that makes up can expression activity.
The building process of the polypeptide vaccine (patent No.: 02137011.7).With coding 200 へ segmental DNA sequence of 213,141 へ, 160 amino acids and linker DNA sequences in the synthetic VP1 gene of chemical method, series connection becomes the primary structure of 141 へ 160AA-200 へ 213AA-141 へ 160AA on gene level, and is inserted into cloning vehicle pBluescriptIIKS.Get 1ug pBluescriptIIKS with EcoR I and BamH I double digestion, in 37 ℃ of reactions two hours, big fragment was reclaimed in the electrophoresis rubber tapping.This large fragment DNA is mixed with the above-mentioned fragment of connecting, under effects such as T4 ligase, coupled reaction takes place.The recombinant DNA transformed into escherichia coli competent cell that obtains is incubated in the ampicillin flat board, and 37 ℃ of inversions are spent the night.Picking white transformant with BstE II single endonuclease digestion, EcoR I and BamH I double digestion, pcr amplification, dna sequencing Analysis and Identification transformant, thereby obtains positive colony.With EcoR I and two above-mentioned positive colony, the electrophoresis rubber tapping recovery small fragments cut of BamH I.With the two expression plasmid carrier pTrcHisA that cut of these two restricted enzyme, big fragment is reclaimed in the electrophoresis rubber tapping equally.In like manner be connected, transform and screen with above-mentioned, finally obtain positive colony, called after pXZ860.
Is fermentation liquid with pXZ860 and pcDNA-IFN with the LB culture fluid, 37 ℃ of mixing speed 6000rpm aerobic culture.PXZ860 induces cultivating the IPTG that 2 hours (OD value about 0.8) back adds final concentration 1mM, continues to cultivate and collects thalline in 8 hours, thalline is suspended in the shell-broken liquid, with the Ultrasound Instrument breaking cellular wall of 95W power 5 minutes again; Ultrasonic back 5000rpm collected antigen protein in centrifugal 20 minutes, it is made into oil emulsion can obtains polypeptide vaccine.The pcDNA-IFN overnight incubation is also collected thalline, with the extensive extracting plasmid DNA of alkaline lysis, utilizes PBS that plasmid is diluted to the novel adjuvant that 1mg/ml can obtain described polypeptide vaccine.
At last above-mentioned vaccine and adjuvant are used for immune foot and mouth disease susceptible animal.Relevant animal disease resistant poison ability test experience the results are shown in Table 1 and table 2.
The sequence that the present invention relates to is as follows:
SEQ?ID?NO.1：
MAPTSAFFTALVLLSCNAICSLGCDLPQTHSLAHTRALRLLAQMRRISPFSCLDHRRDFGFPQEALGGNQVQKAQAM
ALVHEMLQQTFQLFSTEGSAAAWDESLLHQFCTGLDQQLRDLEACVMQEVGLEGTPLLEEDSILAVRKYFHRLTLYL
QEKNYSPCAWEIVRAEVMRVFSSSRNLQDRLRKKE
SEQ?ID?NO.2：
ATGGCCCCAACCTCAGCCTTCTTCACAGCCCTGGTGCTACTCAGCTGCAATGCCATCTGCTCTCTGGGCTGTGACCT
GCCTCAGACCCATAGCCTGGCGCACACCAGGGCCCTGAGGCTCCTGGCACAAATGAGGAGAATCTCCCCCTTCTCCT
GCCTGGACCACAGAAGGGACTTTGGATTCCCCCAAGAGGCCTTGGGGGGCAACCAGGTCCAGAAGGCTCAAGCCATG
GCTCTGGTGCATGAGATGCTCCAGCAGACCTTCCAGCTCTTCAGCACAGAGGGCTCGGCTGCTGCCTGGGATGAGAG
CCTCCTGCACCAGTTCTGCACTGGACTGGATCAGCAGCTCAGGGACCTGGAAGCCTGTGTCATGCAGGAGGTGGGGC
TGGAAGGGACCCCCCTGCTGGAGGAGGACTCCATCCTGGCTGTGAGGAAATACTTCCACAGACTCACCCTCTATCTG
CAAGAAAAGAACTACAGCCCCTGTGCCTGGGAGATCGTCAGGGCAGAAGTCATGAGAGTCTTCTCTTCCTCCAGAAA
CCTGCAAGACAGACTCAGGAAGAAGGAGTGA
Claims (3)
1, a kind of genetic engineering polypeptide vaccine adjuvant for aftosa, it is characterized in that described adjuvant is to be cloned into the recombiant plasmid that carrier for expression of eukaryon obtains by tame pig interferon-α gene by Protocols in Molecular Biology, the aminoacid sequence of this family's pig interferon-α gene code is SEQ ID NO.1, its nucleotides sequence is classified SEQ ID NO.2 as, and carrier for expression of eukaryon is to have the DNA expression vector that eukaryotic promoter, prokaryotic promoter and protokaryon resistant gene are feature.
2, a kind of genetic engineering polypeptide vaccine adjuvant for aftosa, it is characterized in that changing the pig attenuation salmonella over to or tame pig interferon-α gene linked to each other with recombinant adenoviral vector and obtaining by the recombiant plasmid described in the claim 1, the aminoacid sequence of this family's pig interferon-α gene code is SEQ ID NO.1, and its nucleotides sequence is classified SEQ ID NO.2 as.
3, a kind of preparation method of genetic engineering polypeptide vaccine adjuvant for aftosa as claimed in claim 1 comprises that gene preparation, reorganization, protein active are measured and the extensive extracting of expression vector plasmid, it is characterized in that concrete steps are as follows:
(1) by the method for the RT-PCR pig interferon-α gene of must getting home from the total RNA of tame pig liver, the aminoacid sequence of this family's pig interferon-α gene code is SEQ ID NO.1, and its nucleotides sequence is classified SEQ ID NO.2 as;
(2) said gene is inserted procaryotic clone carrier, and transformed into escherichia coli, order-checking also compares with tame pig interferon-α sequence that GenBank provides, has determined to obtain correct gene;
(3) said gene is inserted the construction of eukaryotic expression vector recombiant plasmid, and transformed into escherichia coli, extracting plasmid transfection BHK-21 cell, collect the supernatant culture medium and utilize WISH cell/vesicular stomatitis virus activity determining system and PK15 cell/Pseudorabies virus activity determining system to measure tame pig interferon-alpha active respectively, determine tame pig interferon-α albumen that the recombiant plasmid that makes up can expression activity; Described carrier for expression of eukaryon is to have the DNA expression vector that eukaryotic promoter, prokaryotic promoter and protokaryon resistant gene are feature.
(4) positive strain was collected thalline at 35-40 ℃ of fermentation culture 10-15 hour; Broken thalline and mass preparation expression vector plasmid; Utilize PBS buffer dilution plasmid to suitable concentration, prepare polypeptide vaccine adjuvant of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101476646A CN100548384C (en) | 2006-12-21 | 2006-12-21 | A kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101476646A CN100548384C (en) | 2006-12-21 | 2006-12-21 | A kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1994470A CN1994470A (en) | 2007-07-11 |
| CN100548384C true CN100548384C (en) | 2009-10-14 |
Family
ID=38249725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101476646A Expired - Fee Related CN100548384C (en) | 2006-12-21 | 2006-12-21 | A kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100548384C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102363043B (en) * | 2011-10-09 | 2013-05-01 | 中国农业科学院兰州兽医研究所 | Swine C-type foot-and-mouth disease genetic engineering vaccine adjuvant, and preparation method thereof |
| CN107233568A (en) * | 2017-06-20 | 2017-10-10 | 上海赛伦生物技术股份有限公司 | A kind of immunologic adjuvant of immune horse |
| CN108330134B (en) * | 2018-01-25 | 2021-07-27 | 中国农业科学院兰州兽医研究所 | O-type Fc polypeptide vaccine of swine foot-and-mouth disease virus and preparation method and application thereof |
-
2006
- 2006-12-21 CN CNB2006101476646A patent/CN100548384C/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| Mouse protection test as a predictor of the protectivecapacity of synthetic foot-and-mouth disease vaccines. Melcahy G et al.Vaccine,No.9. 1991 |
| Mouse protection test as a predictor of the protectivecapacity of synthetic foot-and-mouth disease vaccines. Melcahy G et al.Vaccine,No.9. 1991 * |
| 增强疫苗免疫原性的研究进展. 刘明秋等.《国外医学》预防、诊断、治疗用生物制品分册，第24卷第3期. 2001 |
| 增强疫苗免疫原性的研究进展. 刘明秋等.《国外医学》预防、诊断、治疗用生物制品分册，第24卷第3期. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1994470A (en) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101287487A (en) | Agents and methods based on the use of the EDA domain of fibronectin | |
| JPH0797995B2 (en) | Method for producing peptides | |
| CN108324936A (en) | A kind of grass carp reovirus VP35 protein subunit vaccines and its preparation method and application | |
| CN100548384C (en) | A kind of genetic engineering polypeptide vaccine adjuvant for aftosa and its production and application | |
| CN102105163B (en) | Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof | |
| CN106674354A (en) | Fusion protein of chicken interferon IFN-lambda and IFN-alpha | |
| CN106939042B (en) | Porcine alpha interferon and application thereof | |
| CN103570817B (en) | Plasmodium vivax PvMSP1 recombinant antigenic protein as well as preparation method and application thereof | |
| CN102492714A (en) | Method for preparing recombinant Chinese rural dog interferon-alpha | |
| CN107033245A (en) | The preparation method and purposes of the polyclonal antibodies of one breeder caspase 1 | |
| CN1287858C (en) | Foot-and-mouth disease gene engineering polypeptide vaccine and its preparing method | |
| CN108707195B (en) | 3 gene of Mandarin fish IFN-α, recombinant protein, preparation method and application | |
| CN1275649C (en) | Bivalence polypeptide vaccine for resisting A type and O type foot-and-mouth disease virus and its preparation | |
| CN100379863C (en) | Method of preparing natural human thymosin a1 using series expression mode | |
| CN100594931C (en) | The pIFN-gamma gene adjuvant for pig vaccine and its prepn process | |
| CN103014015B (en) | Gene segment for coding porcine interferon-gamma and application of gene segment | |
| CN114874340A (en) | Novel coronavirus spike protein and human gamma interferon fusion protein and preparation method thereof | |
| CN103495159B (en) | The preparation method of flavobacterium columnare genetic vaccine | |
| CN1408434A (en) | Polypeptide and DNA combined vaccine for resisting animal's foot-and-mouth disease and its preparing method | |
| CN112661818A (en) | Canine and cat parvovirus VP2350-420Protein and preparation method and application thereof | |
| EP1007647B1 (en) | High level of expression of ingap | |
| CN102276725A (en) | Cryptosporidium CTL and Th mixed multi-epitope gene and fusion protein and application | |
| CN103865934B (en) | Bungatotoxin antigen epitope gene and application of bungatotoxin antigen epitope gene to preparation of gene vaccine and antigen | |
| CN104001164A (en) | Aeromonas hydrophila heat shock protein subunit vaccine and preparation method thereof | |
| CN110129329A (en) | It is a kind of for expanding the primer and preparation method of Japanese eel interferon correlation factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091014 Termination date: 20141221 |
|
| EXPY | Termination of patent right or utility model |